Molecular genetics of cytochrome P450 IID. Anomalies of drug metabolism.

作者: Stephane Panserat , Evelyne Jacqz-Aigrain , Rajagopal Krishnamoorthy , Lucas Sica

DOI: 10.1007/BF02771762

关键词:

摘要: Drugs are most often hydrophobic substances which, after their administration, must be transformed into hydrophilic compounds in order to facilitate urinary and biliary elimination (1,2). The hepatic metabolism of drugs xenobiotics is classically divided two successive phases. In the course phase I, undergo oxidation reduction reactions hydrolysis. This first metabolic step, referred as funtionalization, largely dominated by catalyzed cytochromes P450 whose characteristic property power metabolize a wide variety substrates, endogenous steroids, drugs, exogenous (1,3). These can lead formation reactive compounds, toxic, accumulation dangerous for organism (4). second

参考文章(43)
MR Law, MR Hetzel, JR Idel, Debrisoquine metabolism and genetic predisposition to lung cancer British Journal of Cancer. ,vol. 59, pp. 686- 687 ,(1989) , 10.1038/BJC.1989.142
U A Meyer, M Blum, R Gaedigk, A Gaedigk, M Eichelbaum, Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. American Journal of Human Genetics. ,vol. 48, pp. 943- 950 ,(1991)
U A Meyer, S Kimura, R C Skoda, F J Gonzalez, M Umeno, The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. American Journal of Human Genetics. ,vol. 45, pp. 889- 904 ,(1989)
Daniel W. Nebert, Masahiko Negishi, Multiple forms of cytochrome P-450 and the importance of molecular biology and evolution Biochemical Pharmacology. ,vol. 31, pp. 2311- 2317 ,(1982) , 10.1016/0006-2952(82)90523-8
Rachel Tyndale, Toshifumi Aoyama, Franck Broly, Tamihide Matsunaga, Tadanobu Inaba, Werner Kalow, Harry V. Gelboin, Urs A. Meyer, Frank J. Gonzalez, Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype. Pharmacogenetics. ,vol. 1, pp. 26- 32 ,(1991) , 10.1097/00008571-199110000-00005
D. M. Jerina, J. W. Daly, Arene oxides: a new aspect of drug metabolism. Science. ,vol. 185, pp. 573- 582 ,(1974) , 10.1126/SCIENCE.185.4151.573
C. Mura, N. Gerard, M. Vincent-Viry, MM Galteau, E. Jacqz-Aigrain, R. Krishnamoorthy, Molecular heterogeneity of the XbaI defined 44kb allele of the CYP2D locus within the Caucasian population. British Journal of Clinical Pharmacology. ,vol. 35, pp. 161- 165 ,(1993) , 10.1111/J.1365-2125.1993.TB05681.X